Helus Pharma Inc.
For the period ended Nov 3, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Nov 3, 2026 · Filed Nov 3, 2026
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
6-K 1 form6k.htm FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month ofNovember, 2026.
Commission File Number:001-40673
Helus Pharma Inc.
(Exact Name of Registrant as Specified in Charter)
**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 **
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HELUS PHARMA INC. | ||
| (Registrant) | ||
| Date: November 3, 2026 | By: | /s/ Greg Cavers |
|---|---|---|
| Name: | Greg Cavers | |
| Title: | Chief Financial Officer |
EXHIBIT INDEX
| 99.1 | News Release dated November 3, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.